Individuals with cystic fibrosis — adults as well infants and children — have long struggled to gain and maintain their weight. But how has the current widespread use of highly effective modulator treatments — HEMT — changed that situation? That’s the focus of this eCysticFibrosis Review Special Edition: CF and Nutrition and HEMT.  The first part of this program presented an evidence-based Expert Commentary on the current status of weight gain, obesity, and nutrition among people with CF by guest author Katie McDonald, PhD, MS, RDN, CSP, a clinical dietitian at Primary Children's Medical Center in Salt Lake City. The second part is a podcast interview, providing further in-depth discussions between Katie McDonald and three top CF nutrition experts.  Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit? Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent’s University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Managing pulmonary exacerbations in people with cystic fibrosis: is there high-grade evidence to support best practices? How helpful is the most current guidance? Does the recent research challenge the current standard of care?  Join us for this eCysticFibrosis Review podcast, as Dr. D.B. Sanders from the Indiana University School of Medicine explains how these questions can affect clinical care. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Race and ethnicity. How do they affect a patient’s ability to receive a timely and accurate cystic fibrosis diagnosis? How do the social determinants of health limit access to appropriate CF treatment and produce poorer outcomes? That’s what we’re here to talk about today with Dr. Jennifer Taylor-Cousar from National Jewish Health and Children’s Hospital Colorado in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Pancreatic insufficiency. In children with CF, it’s been associated with delayed development and increased odds of developing severe lung disease. How can it be more accurately diagnosed? And what does the evidence say about the effects of treatment with CFTR modulators?That’s what we explore in this case-based podcast, with Dr. Vikesh Singh, Associate Professor of Medicine and Director of the Pancreatitis Center at Johns Hopkins Medical Institutions.  Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their patients’ health? What information out there is proved, what’s speculation, and what is simply unknown? These questions are the focus of this eCysticFibrosis Review Special COVID Edition issue. Lisa Saiman MD, MPH, professor of pediatrics at Columbia University Irving Medical Center, analyzes the current literature investigating these questions and then speaks directly with front-line clinicians about what they’re experiencing as they navigate a disrupted health care system. In addition to presenting her analysis of the data-driven evidence describing the effects of the COVID-19 virus on people with cystic fibrosis, Dr. Saiman also spoke directly with front-line CF clinicians to learn about what they’ve been experiencing as they work to maintain effective patient care. Transcripts of these interviews can be accessed throughout the newsletter.Take our post-test to claim CME credits. Hosted on Acast. See acast.com/privacy for more information.

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their patients’ health? What information out there is proved, what’s speculation, and what is simply unknown?  These questions are the focus of this eCysticFibrosis Review Special COVID Edition issue. Hosted on Acast. See acast.com/privacy for more information.

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their patients’ health? What information out there is proved, what’s speculation, and what is simply unknown?  These questions are the focus of this eCysticFibrosis Review Special COVID Edition issue. Hosted on Acast. See acast.com/privacy for more information.

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their patients’ health? What information out there is proved, what’s speculation, and what is simply unknown?  These questions are the focus of this eCysticFibrosis Review Special COVID Edition issue. Hosted on Acast. See acast.com/privacy for more information.

Studies have shown that adolescent and young adult women with cystic fibrosis often turn to their CF care team for answers to their questions about their sexual and reproductive health. But how prepared are CF clinicians to initiate conversations? Do they have the most current data about pregnancy decisions for women taking CFTR modulators? When should modulator therapy be stopped? When is it safe to continue?In this eCysticFibrosis Review podcast, Dr. Traci Kazmerski from UPMC Children's Hospital of Pittsburgh and Dr. Natalie West from Johns Hopkins University take us into the clinic to address these important questions.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Airway infections are a hallmark of cystic fibrosis, making antibiotic therapies a mainstay of CF treatment. While the fight against ABX resistance is ongoing, newer data are showing that commonly used dosing regimens may have to be altered to account for the particular pharmacodynamics in people with CF. How should ABX dosing be altered, and what additional effect might CFTR modulation have on dosing decisions?That’s the topic Dr. Andrea Hahn, Assistant Professor of Pediatrics and an Infectious Disease Specialist at Children’s National Medical Center and George Washington University School of Medicine and Health Sciences, addresses in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

No-contact telemedicine to better protect CF clinic patients and staff during this pandemic may sound like a great idea, but is it even possible to institute? In this eCysticFibrosis Review Special Edition podcast, we find out how pulmonary and critical care specialists Dr. Dana Albon and Dr. Lindsay Somerville successfully brought telemedicine to their Adult Cystic Fibrosis Clinic at University of Virginia Health.Take our post-test to claim CME credits. Hosted on Acast. See acast.com/privacy for more information.

Where, beyond the lungs, do CFTR modulators provide beneficial effects? Can treatment promote growth in height and BMI? What’s known about CFTR modulator effects on cystic fibrosis-associated liver disease?  In this eCysticFibrosis Review podcast, Drs. Darla Shores and Anna Reed from the THRIVE Pediatric Intestinal Rehabilitation Center in the Division of Gastroenterology, Hepatology, and Nutrition at the Johns Hopkins Children's Center take us to the clinic to answer these and other questions crucial to the health of our patients with cystic fibrosis.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Elexacaftor/tezacaftor/ivacaftor — the newly approved triple combination CFTR modulator therapy.  What are the benefits?  For which patients?  What are the potential adverse effects?  Who’s most likely to receive them?  In this issue, Dr. Scott Sagel from the Breathing Institute at the Children’s Hospital Colorado, part of the University of Colorado’s Anschutz Medical Campus, takes us to the clinic to discuss some answers.Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Anxiety and depression in cystic fibrosis — who do these conditions affect? How much do they influence patient health? How can clinicians identify and manage them? What evidence-based interventions have been shown to work?In this issue, Dr. Anna Georgiopoulos, Assistant Professor of Psychiatry, Part-Time, Harvard Medical School and Consulting Psychiatrist, Massachusetts General Hospital Cystic Fibrosis Program, takes us to the clinic to answer these questions that can be key to the health and well-being of children, adults, and families living with CF.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung?  In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies.Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Inhaled antibiotics have become the foundation of treating chronic respiratory tract Pseudomonas infection in individuals with cystic fibrosis. But what happens when inhaled monotherapy doesn’t sufficiently manage the symptoms? Which patients are appropriate candidates for treatment with multiple inhaled agents?  Which medications are appropriate for continuous alternating therapy (CAT)?In this Issue, Dr. Elliott Dasenbrook from the Cleveland Clinic brings the evidence he analyzed in his recent eCysticFibrosis Review Newsletter issue (Vol 8; Issue 10) into the clinic to help guide clinical decision-making.Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

The effects of CFTR modifiers on improving lung function in people with cystic fibrosis are well known. But what about their effects on the GI tract that directly affect nutrition?In this issue, Dr. Michael Wilschanski — Director of Hadassah Hospital’s Pediatric Gastroenterology Unit at Hebrew University in Jerusalem — explains how new findings about CFTR modification can impact clinical practice. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Volume 8, Issue 7. Part 3 Hosted on Acast. See acast.com/privacy for more information.

Volume 8, Issue 7. Part 2 Hosted on Acast. See acast.com/privacy for more information.